Stem Cell Research (Apr 2022)
Establishment and characterization of human induced pluripotent stem cell line from a Parkinson’s disease patient harboring VPS13A gene mutation
- Xianjie Lu,
- Wei Wang,
- Yanming Liu,
- Na Song,
- Mengpeng Li,
- Xin Mu,
- Nan Zhang,
- Qingfa Chen,
- Licheng Jiang,
- Xianglin Kong,
- Peng Sun,
- Jiabei Tong,
- Yunping Zhang,
- Jingtao Li,
- Shengjun Ma,
- Fabin Han
Affiliations
- Xianjie Lu
- The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng People’s Hospital/Liaocheng University, Liaocheng 252000, Shandong, China
- Wei Wang
- The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng People’s Hospital/Liaocheng University, Liaocheng 252000, Shandong, China
- Yanming Liu
- The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng People’s Hospital/Liaocheng University, Liaocheng 252000, Shandong, China
- Na Song
- The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng People’s Hospital/Liaocheng University, Liaocheng 252000, Shandong, China
- Mengpeng Li
- The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng People’s Hospital/Liaocheng University, Liaocheng 252000, Shandong, China
- Xin Mu
- The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng People’s Hospital/Liaocheng University, Liaocheng 252000, Shandong, China
- Nan Zhang
- The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng People’s Hospital/Liaocheng University, Liaocheng 252000, Shandong, China
- Qingfa Chen
- The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng People’s Hospital/Liaocheng University, Liaocheng 252000, Shandong, China
- Licheng Jiang
- The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng People’s Hospital/Liaocheng University, Liaocheng 252000, Shandong, China
- Xianglin Kong
- The Innovation Institute for Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, Shandong, China
- Peng Sun
- The Innovation Institute for Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, Shandong, China
- Jiabei Tong
- Shandong Meijia Therapeutics, Jinan 252013, Shandong, China
- Yunping Zhang
- Department of Dermatology, Liaocheng People’s Hospital, Liaocheng 252000, Shandong, China
- Jingtao Li
- Department of Thoracic Surgery, Liaocheng People’s Hospital, Liaocheng 252000, Shandong, China
- Shengjun Ma
- Department of Cardiac Surgery, Liaocheng People’s Hospital, Liaocheng 252000, Shandong, China; Corresponding authors at: The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng People’s Hospital/Liaocheng University, Liaocheng 252000, Shandong, China (F. Han). Department of Cardiac Surgery, Liaocheng People’s Hospital, Liaocheng 252000, Shandong, China (S. Ma).
- Fabin Han
- The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng People’s Hospital/Liaocheng University, Liaocheng 252000, Shandong, China; The Innovation Institute for Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, Shandong, China; Corresponding authors at: The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng People’s Hospital/Liaocheng University, Liaocheng 252000, Shandong, China (F. Han). Department of Cardiac Surgery, Liaocheng People’s Hospital, Liaocheng 252000, Shandong, China (S. Ma).
- Journal volume & issue
-
Vol. 60
p. 102685
Abstract
Mutations in VPS13 gene have been recently reported as a genetic cause of Parkinson's disease (PD). In this study, we isolated the skin fibroblasts from a PD patient harboring VPS13A gene mutation (c. 4282_4289delinsA) and reprogrammed the fibroblasts to a novel patient-specific induced pluripotent stem cell (iPSC) line LCPHi002-A using transgene-free episomal plasmids to express OCT3/4, SOX2, KLF4, L-MYC, and LIN28. The LCPHi002-A line showed the normal karyotype, expression of pluripotency markers, and had multi-lineage differentiation capacity in vivo. This iPSC line of LCPHi002-A could be used for studying pathogenic mechanisms of PD.
